BACKGROUND
Transplantation with allogeneic cells has become a promising modality for
cancer therapy, which can induce graft-versus-
tumor (GVT) effect. This study was aimed at assessing the safety, efficacy, and tissue type GVT (tGVT) response of
transplantation with allogeneic skin
tumors to treat chemically-induced skin
tumors in mice. MATERIAL AND METHODS FVB/N and ICR mice were exposed topically to chemicals to induce skin
tumors. Healthy ICR mice were transplanted with allogeneic skin
tumors from FVB/N mice to test the safety. The
tumor-bearing ICR mice were transplanted with, or without, allogeneic skin
tumors to test the efficacy. The
body weights (BW), body condition scores (BCS),
tumor volumes in situ,
metastasis tumors, overall survival, and serum
cytokines were measured longitudinally. RESULTS
Transplantation with no more than 0.03 g allogeneic skin
tumors from FVB/N mice to healthy ICR mice was safe. After
transplantation with allogeneic skin
tumors to treat
tumor-bearing mice, it inhibited the growth of
tumors slightly at early stage, accompanied by fewer metastatic
tumors at 24 days after
transplantation (21.05% vs. 47.37%), while there were no statistically significant differences in the values of BW, BCS,
tumor volumes in situ,
metastasis tumors, and overall survival between the transplanted and non-transplanted groups. The levels of serum
interleukin (IL)-2 were significantly reduced in the controls (P<0.05), but not in the recipients, which may be associated with the tGVT response. CONCLUSIONS Our results suggest that
transplantation with allogeneic skin
tumors is a safe treatment in mice, which can induce short-term tGVT response mediated by
IL-2.